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The rate of increase of longevity has varied considerably across U.S. states since 1991.  This paper
examines the effect of the quality of medical care, behavioral risk factors (obesity, smoking, and AIDS
incidence), and other variables (education, income, and health insurance coverage) on life expectancy
and medical expenditure using longitudinal state-level data. We examine the effects of three different
measures of the quality of medical care.  The first is the average quality of diagnostic imaging procedures,
defined as the fraction of procedures that are advanced procedures.  The second is the average quality
of practicing physicians, defined as the fraction of physicians that were trained at top-ranked medical
schools.  The third is the mean vintage (FDA approval year) of outpatient and inpatient prescription
drugs. Life expectancy increased more rapidly in states where (1) the fraction of Medicare diagnostic
imaging procedures that were advanced procedures increased more rapidly; (2) the vintage of self-
and provider-administered drugs increased more rapidly; and (3) the quality of medical schools previously
attended by physicians increased more rapidly.  States with larger increases in the quality of diagnostic
procedures, drugs, and physicians did not have larger increases in per capita medical expenditure.
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frank.lichtenberg@columbia.eduDuring the twentieth century, U.S. life expectancy at birth increased by almost 30 
years (63%), from 47.3 years in 1900 to 77.0 years in 2000.  Nordhaus (2002) estimated 
that, “to a first approximation, the economic value of increases in longevity over the 
twentieth century is about as large as the value of measured growth in non-health goods 
and services” (p. 17).  Murphy and Topel (2005) observed that “the historical gains from 
increased longevity have been enormous. Over the 20th century, cumulative gains in life 
expectancy were worth over $1.2 million per person for both men and women. Between 
1970 and 2000 increased longevity added about $3.2 trillion per year to national wealth, 
an uncounted value equal to about half of average annual GDP over the period.” 
  The rate of increase in longevity has varied considerably across states.  Figure 1 
shows the increase in life expectancy at birth during the period 1991-2004,
1 by state.  In 
the eight states with the smallest increase, life expectancy increased by only 0.31-1.16 
years.  In the eight states with the largest increase, life expectancy increased by 2.5-4.3 
years.  This paper seeks to help answer the question, why has longevity increased faster 
in some states than other states?   
Longevity is likely to depend on a number of factors, including the quality of 
medical care, exogenous changes in disease incidence (e.g. the appearance of new 
diseases such as HIV/AIDS), income, education, and behavioral risk factors (e.g., obesity 
and smoking).  By analyzing longitudinal state-level data, we can measure and control for 
many of these factors.  We can also control for the effects of unobserved factors that vary 
across states but are relatively stable over time (e.g. climate and environmental quality), 
and unobserved factors that change over time but are invariant across states (e.g. changes 
in Federal government policies).  In addition to interstate variation in longevity growth, 
we will analyze the growth of per capita medical expenditure. 
  The overall conceptual framework of the paper is depicted in Figure 2.   
 
                                                 
1 Due to limitations on available data, this paper will analyze changes in longevity during the period 1991-
2004.   2
 
 
Previous literature suggests that technological innovation in general, and new goods in 
particular, play a key role in economic growth.  In Section I, we describe our indicators 
of the quality of medical care.  Section II describes the econometric models we will 
estimate.  Section III describes the data sources and presents some descriptive statistics.  
Empirical results are presented in Section IV.  Some additional evidence (based on 
Australian data) about the impact of advanced imaging technology on mortality is 
presented in Section V.  The final section presents a summary and conclusions. 
 
I.  Indicators of the quality of medical care 
 
We will examine the effects of three different measures of the quality of medical 
care.  The first is the average quality of diagnostic imaging procedures, defined as the 
fraction of procedures that are advanced procedures.  The second is the average quality of 
practicing physicians, defined as the fraction of physicians that were trained at top-ranked 
medical schools.  The third is the mean vintage (FDA approval year) of outpatient and 
impatient prescription drugs.   
Some of the indicators of the quality of medical care we examine measure the 
relative utilization of new vs. old medical goods and services, or the degree of influence 
of medical research.  Economists believe that new goods and services, which are 
•  Indicators of the quality of medical care 
o  Use of advanced diagnostic imaging 
technology 
o  Quality of physicians 
o  Vintage of outpatient and inpatient 
prescription drugs 
•  Behavioral risk factors 
o  AIDS incidence 
o  BMI 
o  Smoking 
•  Health insurance coverage 
•  Per capita income 
•  Educational attainment 
•  State fixed effects 
•  Year fixed effects 
•  Life expectancy at 
birth 
•  Per capita medical 
expenditure 
Figure 2 
Conceptual framework   3
generated by public and private investment in research and development, are the main 
reason why people are better off today than they were several generations ago.  Grossman 
and Helpman (1993) argued that “innovative goods are better than older products simply 
because they provide more ‘product services’ in relation to their cost of production.”  
Bresnahan and Gordon (1996) stated simply that “new goods are at the heart of economic 
progress.” Jones (1998) argues that “technological progress [is] the ultimate driving force 
behind sustained economic growth” (p.2), and that “technological progress is driven by 
research and development (R&D) in the advanced world” (p. 89).  Bils (2004) makes the 
case that “much of economic growth occurs through growth in quality as new models of 
consumer goods replace older, sometimes inferior, models.” 
One way to measure utilization of medical innovations is to measure the mean 
vintage of medical goods and services used.  The vintage of a good is the year in which 
the good was first used.  For example, the vintage of the drug atorvastatin (Lipitor) is 
1997—the year the drug was approved by the FDA.  We seek to test the hypothesis that, 
ceteris paribus, people using newer, or later vintage, medical goods and services will be 
in better health, and will therefore live longer.  This hypothesis is predicated on the idea 
that these goods and services, like other R&D intensive products, are characterized by 
embodied technological progress.
2   
A number of econometric studies (Bahk and Gort (1993), Hulten (1992), 
Sakellaris and Wilson (2001, 2004)) have investigated the hypothesis that capital 
equipment employed by U.S. manufacturing firms embodies technological change, i.e. 
that each successive vintage of investment is more productive than the last. 
  Equipment is 
expected to embody significant technical progress due to the relatively high R&D-
intensity of equipment manufacturers.  The method that has been used to test the 
equipment-embodied technical change hypothesis is to estimate manufacturing 
production functions, including (mean) vintage of equipment as well as quantities of 
                                                 
2 Solow (1960, p 91): argued that “many if not most innovations need to be embodied in new kinds of 
durable equipment before they can be made effective.  Improvements in technology affect output only to 
the extent that they are carried into practice either by net capital formation or by the replacement of old-
fashioned equipment by the latest models…”  We hypothesize that innovations may be embodied in 
nondurable goods (e.g. drugs) and services as well as in durable equipment. 
   4
capital and labor.  These studies have concluded that technical progress embodied in 
equipment is a major source of manufacturing productivity growth.   
  Although most previous empirical studies of embodied technical progress have 
focused on equipment used in manufacturing, embodied technical progress may also be 
an important source of economic growth in health care.  According to the National 
Science Foundation, in 1997, “medical substances and devices firms had by far the 
highest combined R&D intensity at 11.8 percent,…well above the 4.2-percent average for 
all 500 top 1997 R&D spenders combined. The information and electronics sector ranked 
second in intensity at 7.0 percent.”
3 
 
A.  Quality of diagnostic imaging procedures  
 
Our measure of the quality of diagnostic imaging procedures is defined as 
follows: 
 




ADV_IMAGE%st = the fraction of standard or advanced Medicare imaging 
procedures performed in state s in year t that were advanced 
procedures 
N_ADV_IMAGEst = the number of advanced Medicare imaging procedures performed 
in state s in year t 
N_STD_IMAGEst = the number of standard Medicare imaging procedures performed 
in state s in year t 
Data on the number of procedures (submitted services), by Healthcare Common 
Procedure Coding System (HCPCS) code,
4 carrier,
5 and year, where obtained from the 
1991-2004 Physician/Supplier Procedure Summary Master Files.
6  These files are 100% 
                                                 
3 National Science Foundation, U.S. Corporate R&D: Volume 1: Top 500 Firms in R&D by Industry 
Category, http://www.nsf.gov/statistics/nsf00301/expendit.htm.  The pattern of 1997 R&D spending per 
employee is similar to that for R&D intensity, with medical substances and devices again the highest at 
$29,095 per employee. Information and electronics is second at $16,381. Combined, the top 500 1997 
R&D firms spent $10,457 per employee. 
4 http://en.wikipedia.org/wiki/Healthcare_Common_Procedure_Coding_System 
5 In most cases, there is a one-to-one correspondence between a Medicare carrier and a state. 
6 
http://www.cms.hhs.gov/NonIdentifiableDataFiles/06_PhysicianSupplierProcedureSummaryMasterFile.asp    5
summaries of all Part B Carrier and DMERC Claims processed through the Common 
Working File and stored in the National Claims History Repository.  
We used Berenson-Eggers Type of Service (BETOS) codes developed by CMS to 
distinguish between standard and advanced imaging procedures.  The BETOS coding 
system was developed primarily for analyzing the growth in Medicare expenditures.          
The coding system covers all HCPCS codes; assigns a HCPCS code to only one BETOS 
code; consists of readily understood clinical categories (as opposed to statistical or 
financial categories); consists of categories that permit objective assignment; is stable 
over time; and is relatively immune to minor changes in technology or practice patterns.
7  
Advanced imaging procedures (with a BETOS code beginning with I2) involve either a 
computed tomography (CT) scan
8 or magnetic resonance imaging (MRI).
9  Standard 
imaging procedures have BETOS codes beginning with I1. 
According to the 2006 BETOS Public Use File, 544 HCPCS codes correspond to 
standard imaging procedures, and 152 HCPCS codes correspond to advanced imaging 
procedures.  For example, code 71010 (Radiologic examination, chest; single view, 
frontal) is a standard imaging procedure, and code 70450 (Computed tomography, head 
or brain; without contrast material) is an advanced imaging procedure. 
  As shown in Figure 3, nationwide the fraction of imaging procedures that were 
advanced increased from 9.3% in 1991 to 18.8% in 2004.  As shown in Figure 4, the 
fraction of imaging procedures that were advanced in 2004 was 16-17% in the lowest six 
states, and 20-24% in the highest six states. 
 
B.  Physician quality 
 
Our measure of the quality of practicing physicians is the fraction of physicians 
practicing in a state that graduated from a top-ranked medical school.  Data on the 
number of practicing physicians, by state, medical school attended, and year, were 
                                                 
7 http://www.cms.hhs.gov/HCPCSReleaseCodeSets/20_BETOS.asp#TopOfPage  
8 A computed tomography scan is a study that uses a series of X-Rays to create image "slices" of the body. 
9 MRI is a medical imaging technique most commonly used in radiology to visualize the structure and 
function of the body. It provides detailed images of the body in any plane. MRI provides much greater 
contrast between the different soft tissues of the body than CT does, making it especially useful in 
neurological (brain), musculoskeletal, cardiovascular, and oncological (cancer) imaging.   6
obtained from the American Medical Association.  Medical school rankings in terms of 
research and primary care were obtained from the US News and World Report survey of 
U.S. medical schools conducted in Fall 2007.  The medical school research ranking is 
based on a weighted average of eight indicators, and the primary-care ranking is based on 
seven indicators. Both rankings are based on a weighted average of indicators; four of the 
data indicators are used in both the research and primary-care ranking model. The 
research ranking factors in research activity; the primary-care ranking adds a measure of 
the proportion of graduates entering primary-care specialties.  The methodology 
underlying the rankings is described in Appendix A.  As shown in Table 1, research rank 
and primary care rank are not highly correlated. 
We constructed two measures of physician quality: 
MD_RESEARCH_QUALst = ∑m (TOP_RESEARCHm N_MDmst) / ∑m N_MDmst 
MD_PRIMCARE_QUALst = ∑m (TOP_PRIMCAREm N_MDmst) / ∑m N_MDmst 
where 
MD_RESEARCH_QUALst  = the fraction of physicians practicing in state s in year t 
who were graduates from the top 60 medical schools 
ranked in terms of research 
MD_PRIMCARE_QUALst  = the fraction of physicians practicing in state s in year t 
who were graduates from the top 60 medical schools 
ranked in terms of primary care 
TOP_RESEARCHm  = 1 if medical school m was one of the top 60 medical 
schools ranked in terms of research 
= 0 otherwise 
TOP_PRIMCAREm  = 1 if medical school m was one of the top 60 medical 
schools ranked in terms of primary care 
= 0 otherwise 
N_MDmst  = the number of physicians who were graduates from 
medical school m and who are practicing in state s in year t 
 
As shown in Table 2, the mean values of both measures of physician quality 
declined slightly during the period 1991-2004.  The fraction of practicing physicians who 
graduated from the top 60 medical schools ranked in terms of research declined from 
45.2% to 41.0%, and the fraction of physicians who graduated from the top 60 medical 
schools ranked in terms of primary care declined from 40.0% to 37.5%.  As shown in 
Figures 5 and 6, in 2004 both measures of physician quality exhibited significant 
interstate variation.   7
C.  Quality of outpatient and inpatient prescription drugs 
 
 
  The general definition of vintage we will use is: 
 
vintit = Σp freqpit vintp  
      Σa freqpit 
where 
vintit  = the mean vintage of products and services used in state i in year t 
freqpit  = the frequency of use of product or service p in state i in year t 
vintp  = the vintage (year of first use) of product or service p 
 
We will measure the mean vintage of outpatient prescription drugs paid for by the 
state’s Medicaid program, and the mean vintage of drugs administered by providers (e.g., 
chemotherapy) to Medicare beneficiaries.  The number of prescriptions paid for by 
Medicaid is very large: according to the Medical Expenditure Panel Survey, in 1997, 
Medicaid paid for about 201 million prescriptions—11% of all U.S. prescriptions.  
Moreover, we show in Appendix B that the extent of utilization of new drugs in the 
Medicaid program is strongly correlated with the extent of utilization of new drugs in 
general: the vintage of non-Medicaid (and all) rx’s tended to increase more in states with 
larger increases in the vintage of Medicaid rx’s. 
Drugs administered by providers are quite different from self-administered drugs, 
and Medicare pays for a substantial fraction of the former.  In 2004, Medicare paid 
providers $7.6 billion for performing 522 million pharmaceutical procedures.
10   
 
D.  Adjusting for state-specific changes in the distribution of disease 
 
If there have been state-specific changes in the distribution of disease, and drug 
vintage is correlated with disease severity (e.g., newer drugs tend to be for less severe 
diseases), the coefficient on drug vintage could be biased.  However, we can eliminate 
any potential bias by constructing an alternative (fixed-weighted) index of drug vintage. 
Consider the following simplified model of life expectancy: 
LE = β1 V + β2 S 
                                                 
10 Source: CMS, Medicare Part B Physician/Supplier Data by BETOS, Calendar Year 2004, 
http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/Downloads/BETOS04.pdf.   8
where LE = life expectancy, V = drug vintage, and S = (mean) disease severity.  Hence 
ΔLE = β1 ΔV + β2 ΔS 
Suppose that β1 > 0 and that β2 < 0.  For simplicity, suppose that there are just 2 diseases: 
a high-severity disease and a low-severity disease.  Mean disease severity depends on the 
proportions of patients with each disease: 
S = high% SH + (1 – high%) SL = SL + (SH – SL) high% 
where high% = the percent of patients with the high-severity disease, SH = severity of the 
high-severity disease, SL = severity of the low-severity disease, and SH > SL.  Assuming 
that SH and SL are constant, ΔS = (SH – SL) Δhigh%, and  
ΔLE = β1 ΔV + β2 (SH – SL) Δhigh% 
The change in life expectancy is directly related to the change in drug vintage and 
inversely related to the change in the percent of patients with the high-severity disease. 
Suppose that drugs for the low-severity disease (nervous system disorders) tend to 
be newer than drugs for the high-severity disease (cardiovascular disease), so that there is 
an inverse correlation across states between ΔV and Δhigh%: states with smaller 
increases in mean severity will have larger increases in drug vintage.  In this case, failure 
to control for changes in severity (Δhigh%) will result in overestimation of the effect of 
drug vintage on life expectancy. 
We will control for the incidence of one highly severe disease—AIDS—but 
unfortunately data on the incidence of other diseases, by state and year, are not available.   
Therefore direct measurement of mean disease severity (or the percent of patients with 
high-severity diseases) by state and year is not feasible.  However, provided that the 
distribution of drugs utilized, by therapeutic class, is closely related to the distribution of 
patients, by disease, we can eliminate any potential bias in the vintage coefficient by 
using the following fixed-weighted index of drug vintage: 
V’it = Σc class%ci. Vcit 
where Vcit = the mean vintage of prescriptions in therapeutic class c in state i in year t, 
and class%ci. = the mean fraction of prescriptions in therapeutic class c in state i during 
the entire sample period, i.e. class%ci. = (1 / T) Σt class%cit, where class%cit = the fraction 
of prescriptions in therapeutic class c in state i in year t.     9
Changes over time in the fixed-weighted index V’ are entirely due to within-
therapeutic class changes in drug vintage, not at all to between-class changes, i.e. shifts in 
the distribution of drugs by therapeutic class.  In contrast, changes in the standard vintage 
index (Vit = Σc class%cit Vcit) are due to between- as well as within-class changes in 
vintage. 
We will construct fixed-weighted indices of drug vintage using data from the 
Veterans Administration’s National Drug File (U.S. Dept. of Veterans Affairs  (2007)) on 
the therapeutic class of each product.  The VA drug classification is hierarchical, and has 
over 500 classes and subclasses.  We will classify drugs at the highest level of the VA 
classification system, which has 32 classes.  Table 3 shows data on the distribution and 
vintage of Medicaid prescriptions in 1991 and 2004, by major VA therapeutic class.  In 
2004, two classes of drugs (central nervous system medications and cardiovascular 
medications) accounted for half of Medicaid prescriptions.  The share of Medicaid 
prescriptions that were central nervous system medications increased from 19% in 1991 
to 29% in 2004.  The mean vintage of central nervous system medications increased 
much more than the mean vintage of cardiovascular medications (16.5 years vs. 6.5 
years).  However for the nation as a whole, the fixed-weighted vintage index increased 
more during 1991-2004 than the standard index (11.4 years vs. 9.4 years). 
We will estimate models using both the standard index and the fixed-weighted 
index of drug vintage.  Performing this sensitivity analysis is useful, but eliminating the 
effects of shifts in the distribution of drugs by therapeutic class on vintage is not 
necessarily appropriate.  If the rate of innovation varies across diseases/drug classes, 
states may benefit from innovation by changing the distribution of drugs consumed, by 
class, as well as by using newer drugs within drug classes. 
 
E.  Potential reasons for variation in the rate of increase of drug vintage 
 
The rate of increase in drug vintage may vary across states due to both interstate 
differences in the types of diseases afflicting the population, and differences in the drugs 
used to treat given diseases.  Suppose that   
ΔVi = Σd sharedi ΔVd   10
where 
ΔVi  = the increase in the mean vintage of drugs in state i 
sharedi  = the fraction of state i’s residents who have disease d 
ΔVd  = the increase in the mean vintage of drugs to treat disease d 
 
Even if the increase in the mean vintage of drugs to treat each disease is the same in 
every state, differences in the fractions of state residents who have various diseases 
(sharedi) will result in interstate variation in the increase in the mean vintage of drugs.
11 
  The relative incidence of various diseases does vary across states.  This is 
illustrated by Figure 7, which plots the state-level incidence rate (cases per 100,000) of 
colon & rectum cancer against the incidence rate of prostate cancer for males in 2002.  
The correlation across states between these two incidence rates is not significantly 
different from zero (p-value = 0.61). 
Moreover, due to medical practice variation, the increase in the mean vintage of 
drugs to treat any given disease is likely to vary across states.  Medical practice variation 
is a well-documented phenomenon: there are 2514 citations for this term in the PubMed 
database.  The Dartmouth Atlas of Health Care Project (Wennberg (2006)) has 
demonstrated “glaring variations in how health care is delivered across the United 
States.”  
Skinner and Staiger (2005) argue that medical practice variation may be partly 
due to variation in the frequency and likelihood of informational exchanges through 
networks or other social activities, which may in turn be related to both average 
educational attainment and other measures of social capital.  They compared the adoption 
of several important innovations during the 20th century, ranging from advances at mid-
century in hybrid corn and tractors, to medical innovations in the treatment of heart 
attacks at the end of the century. They found a very strong state-level correlation with 
regard to the adoption of new and effective technology, and this correlation held across a 
variety of industries and time periods. These results are suggestive of state-level factors 
associated with barriers to adoption.  These barriers may be related to information or 
network flows, given that farmers, physicians, and individual computer users conduct 
                                                 
11 Our econometric model will control (via state fixed effects) for the effects of permanent, or relatively 
stable, differences between states in the relative incidence of various diseases.   11
their business in often small and isolated groups, and therefore are most vulnerable to 
potential information asymmetries. 
Interstate differences in government health care policy also contribute to practice 
variation.  In the last few years, some state Medicaid programs and private managed care 
plans have restricted access to certain drugs, especially newer, more expensive drugs.  
One important type of restriction is a “prior authorization” requirement: a prescription 
will not be dispensed without prior authorization by program officials.  Lichtenberg 
(2005d) examined the effect of access restrictions on the vintage of drugs used by 
Medicaid enrollees.   The sample included 50 brand name drugs in six important 
therapeutic classes: antidepressants, antihypertensives, cholesterol-lowering drugs, 
diabetic drugs, osteoporosis/menopause drugs, and pain management medications.  The 
extent of access restrictions varied considerably across states.  Twelve states did not 
restrict any of the 50 drugs.  Five states restricted over 47% of the drugs, and one—
Vermont—restricted 43 of the 50 drugs.  The vintage of Medicaid prescriptions increased 
more slowly in states that imposed more access restrictions.
12   
 
II.  Econometric model 
 
  We will investigate the effects of indicators of the quality of medical care, 
behavioral risk factors, and other variables on life expectancy and medical expenditure by 
estimating models of the following form: 
 
Yst =  β Xst + αs + δt + εst    (s = 1,…,50;
13 t = 1991,…,2004)  (1)   
 
where Y is one of the following variables: 
LEst   = life expectancy at birth in state s in year t 
expendst  = the log of per capita medical expenditure in state s in year t 
 
and X includes a subset of the following variables: 
 
                                                 
12 Lichtenberg (2006) presents a theoretical argument that the vintage of drugs is also likely to depend on 
the extent of prescription drug coverage, and empirical evidence that supports this argument. 
13 Arizona is excluded from the sample because it does not participate in the Medicaid Drug Rebate 
Program.   12
adv_image%st  = the fraction of standard or advanced Medicare imaging 
procedures performed in state s in year t that were advanced 
procedures 
vint_medicaid_rxst  = the mean vintage of Medicaid prescriptions in state s in year 
t 
vint_medicaid_rx_fixedst  = a fixed-weight index of the mean vintage of Medicaid 
prescriptions in state s in year t 
vint_medicare_rxst  = the mean vintage of Medicare drug treatments in state s in 
year t 
md_research_qualst  = the fraction of physicians practicing in state s in year t who 
graduated from the top 60 medical schools ranked in terms of 
research 
md_primcare_qualst  = the fraction of physicians practicing in state s in year t who 
graduated from the top 60 medical schools ranked in terms of 
primary care 
incomest  = the log of per capita personal income in state s in year t 
edust  = an index of mean educational attainment of residents of 
state s in year t 
health_covst  = the % of residents covered by health insurance in state s in 
year t 
bmi_gt25st  = the % of residents with BMI > 25 in state s in year t 
now_smokest  = the % of residents who are current smokers in state s in year 
t 
aidsst-2  = the number of AIDS (Acquired Immune Deficiency 
Syndrome) cases reported per 100,000 population in state s in 
year t-2 
 
αs and δt represent state fixed effects and year fixed effects, respectively.  Eq. (1) will be 
estimated by weighted least squares (WLS), weighting by popit, state i’s population in 
year t. 
  In principle, there is some risk of feedback, or reverse causality, from life 
expectancy to some of the explanatory variables, especially mean income and education.  
Ceteris paribus, increases in life expectancy lead to an increase in the fraction of the 
population that is elderly.  As shown in Figure 8, mean income and education of elderly 
people is significantly lower than that of non-elderly people.  Hence unobserved shocks 
that increase a state’s longevity could reduce its mean income and education, causing a 
downward bias in the coefficients of these variables.  However, the share of the 
population that is elderly need not be increasing faster in states with larger increase in life 
expectancy; these states could have higher birth and/or net immigration rates.     13
  In practice, the share of the population that is elderly is increasing faster in states 
with larger increase in life expectancy, but the relationship is not very strong.   By using 
estimates of this relationship and the age profiles shown in Figure 8, we obtained 
estimates of the feedback effect of life expectancy on income and education, via 
population age structure.  These calculations indicated that the downward biases in the 
income and education coefficients in the longevity equations would be extremely small. 
 
III.  Data sources and descriptive statistics 
 
Life expectancy.  The government does not publish data on life expectancy, by state, so 
we constructed estimates using data on the number of deaths by age group, year, and state 
of residence from the Multiple Cause-of-Death Mortality Data from the National Vital 
Statistics System of the National Center for Health Statistics.
14 Each record in the 
microdata is based on information abstracted from death certificates filed in vital 
statistics offices of each State and District of Columbia. The average number of records 
(deaths) per year is about 2.3 million.  We also used population data from CDC Wonder 
Bridged-Race Population Estimates (Vintage 2004, http://wonder.cdc.gov/Bridged-Race-
v2004.HTML).
15  As shown in Figure 9, the population-weighted means of my state 
estimates of LE are quite similar to the NCHS national estimates. 
Per capita income.  These data were obtained from the Bureau of Economic Analysis 
State Annual Personal Income database (http://www.bea.gov/regional/spi/). 
Per capita medical expenditure.  The CMS Health Accounts by State database provides 
data on the following categories of personal health care expenditure, by state and year 
(1980-2004). 
Vintage of Medicaid prescriptions.  The mean vintage of Medicaid prescriptions is 
defined as follows: 
 
vint_medicaid_rxit = Σa n_medicaid_ingredait vinta  
         Σa n_medicaid_ingredait 
                                                 
14 Murray et al (2006) also computed state and local estimates of life expectancy. 
15 We computed life expectancy using the following age classification: under 1 year, 1-4 years, 5-9 years, 
10-14 years, 15-19 years, 20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 years, 50-
54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 80-84 years, 85 years and over.   14
       
where  
 
n_medicaid_ingredait  = the number of Medicaid prescriptions containing active 
ingredient a in state i in year t 
vinta  = the vintage (year of initial FDA approval) of active ingredient a. 
 
The first of these variables is constructed as follows: 
 
n_medicaid_ingredait = Σp n_medicaid_prodpit dpa  
 
where  
n_medicaid_prodpit  = the number of Medicaid prescriptions for product p in state i in 
year t 
dpa = 1 if product p contains active ingredient a 
= 0 if product p does not contain active ingredient a 
 
Σa dpa = 1 if product p is a single-ingredient product; Σa dpa > 1 if it is a combination 
product.  Data on n_medicaid_prodpit were obtained from CMS’ Medicaid State Drug 
Utilization files (http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list.asp), 
which cover outpatient drugs paid for by State Medicaid agencies since the inception of 
the Medicaid Drug Rebate Program.  Forty nine states (Arizona is excluded) and the 
District of Columbia cover drugs under the Medicaid Drug Rebate Program.  The 
Medicaid data disclose the number of prescriptions, by product (NDC code), state, and 
year.  There are currently over 37,000 products in the Medicaid Drug Product Data file 
(http://www.cms.hhs.gov/MedicaidDrugRebateProgram/09_DrugProdData.asp).   
Data on dpa were obtained from the ndc_denorm table in the Multum Lexicon 
database (http://www.multum.com/Lexicon.htm).  There are currently over 2100 active 
ingredients in this database.  Table 4 shows the top 25 active ingredients contained in 
2004 Medicaid prescriptions, ranked by number of prescriptions. 
  Data on vinta were obtained from the Drugs@FDA database, produced by the 
FDA Center for Drug Evaluation and Research 
(http://www.fda.gov/cder/drugsatfda/datafiles/default.htm).  This database includes 
several tables.  The product table enumerates properties of the products included in each 
application, including their active ingredient(s).   The supplements table provides the 
approval history for each application, including dates of approval.  We define vinta as the 
earliest approval date of any product that contains active ingredient a.   15
Vintage of Medicare drug treatments.  Medicare is a health insurance program for people 
age 65 or older, people under age 65 with certain disabilities, and people of all ages with 
End-Stage Renal Disease (permanent kidney failure requiring dialysis or a kidney 
transplant).  All Medicare enrollees are covered by Medicare Part A (Hospital Insurance).  
Most Medicare enrollees elect to pay a monthly premium for Part B. Medicare Part B 
helps cover doctors’ services and outpatient care. It also covers some other medical 
services that Part A doesn’t cover, such as some of the services of physical and 
occupational therapists, and some home health care. Part B helps pay for these covered 
services and supplies when they are medically necessary.  In 2004, about 39 million 
Americans were enrolled in Medicare Part B. 
Prior to January 1, 2006, when Medicare Part D was established, Medicare did not 
pay for most outpatient drugs, but the Medicare Part B (Medical Insurance) program did 
pay for drugs administered by health care providers, e.g. chemotherapy.   
The Medicare drug vintage measure is similar to the Medicaid drug vintage 
measure, with one exception.  For reasons discussed below, the Medicare index is 
expenditure-weighted, rather than quantity weighted: 
 
vint_medicare_rxit = Σa expend_medicare_ingredait vinta  
     Σa expend_medicare_ingredait 
where 
 
expend_medicare_ingredait = expenditure on Medicare drug treatments containing 
active ingredient a in state i in year t 
 
This variable is defined as follows: 
 




expend_medicare_drugdit    = expenditure on Medicare drug treatment d in state i in year t 
eda   = 1 if Medicare drug treatment d contains active ingredient a 
   = 0 if Medicare drug treatment d does not contain active 
ingredient a 
 
Data on expend_medicare_drugdit were obtained from annual Physician/Supplier 
Procedure Summary (PSPS) Master Files produced by CMS for each of the years 1991-  16
2004.  Each file is a 100% summary of all Part B Carrier and DMERC Claims processed 
through the Common Working File and stored in the National Claims History Repository.  
The files are large; the 2004 file has over 12 million records.  The file enables us to 
compute total submitted services and charges, total allowed services and charges, total 
denied services and charges, and total payment amounts, by Medicare carrier and 
procedure.  In most cases there is a one-to-one correspondence between a carrier and a 
state, so we can measure utilization and expenditure, by procedure and state. 
As discussed in the technical documentation for the PSPS Master Files, Medicare 
carriers often make erroneous reports of service counts, but not of expenditures: 
Service counts for drugs should be reported using pricing units, e.g. J0120: 
Injection, Tetracycline up to 250 mg.  In this example, 250 mg = 1 pricing unit or 
service.  If the injection were for 500 mg then the pricing unit or service would be 
equal to 2, i.e. 500mg / 250mg = 2 pricing units or services.  Many carriers are 
reporting the milligrams in the service count and MTUS Fields, e.g. 250 mg 
instead of 1 pricing unit.  As a result the number of services are inflated, thereby 
deflating the average allowed charge.
16 
 
These reporting errors appear to cause spurious fluctuations in aggregate Medicare drug 
treatment service counts, but not in expenditures.  Therefore, while we believe that a 
quantity-weighted vintage index is preferable to an expenditure-weighted index, due to 
errors in reporting service counts we will use an expenditure-weighted index of Medicare 
drug treatments. 
Data on eda were obtained from the ndc_denorm table in the Multum Lexicon 
database. 
Table 5 shows the top 25 active ingredients contained in 2004 Medicare drug 
treatments, ranked by total services count.  Comparison of Tables 4 and 5 indicates that 
the drugs administered by providers to Medicare beneficiaries are quite different from 
outpatient drugs used by Medicaid beneficiaries. 
Demographic characteristics and behavioral risk factors.  Data on body mass index 
(BMI), current smoking participation, health insurance coverage, and educational 
attainment were obtained from the Behavioral Risk Factor Surveillance System (BRFSS), 
which is the world’s largest telephone survey.  The BRFSS was established by the CDC 
                                                 
16 Source: CMS, “2004 Limitations for the Physician/Supplier Procedure Summary Master File.”   17
in 1984, and was designed to collect state-level data.  By 1994, all states, the District of 
Columbia, and three territories were participating in the BRFSS.   
  Data on the incidence of AIDS (the number of AIDS cases reported by state and 
local health departments) were obtained from the CDC’s AIDS Public Information Data 
Set (http://www.cdc.gov/hiv/software/apids.htm).  This data set contains counts of AIDS, 
by demographics; location (region and selected metropolitan areas); case-definition; 
month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV 
exposure group (risk factors for AIDS).  The data set covers the period 1981-2002.  As 
noted above, the measure of aids incidence we will include in our model of life 
expectancy will be the number of AIDS cases reported per 100,000 population lagged 
two years.  Using this measure allows us to have the sample period end in 2004 rather 
than 2002.  Also, Lichtenberg (2006) provides evidence that even before highly-active 
retroviral therapy was introduced in the mid-1990s, life expectancy of AIDS patients at 
time of diagnosis was 3.7 years, so overall life expectancy may depend on lagged AIDS 
incidence more than it depends on contemporaneous AIDS incidence.
17   
Table 6 shows population-weighted sample means of the variables included in eq. 
(1), by year.  Figure 10 shows the increase in the fixed-weighted drug vintage index 
1991-2004, by state 
 
IV.  Empirical results 
 
A.  Life expectancy 
 
Estimates of models of life expectancy at birth are shown in the top half of Table 
7.  The dependent variable in models 1-3 is life expectancy at birth.
18  The three models 
include different sets of indicators of the quality of medical care.  Model 1 includes the 
basic Medicaid drug vintage measure vint_medicaid_rx (with changing therapeutic-class 
weights) and both measures of physician quality (md_primcare_qual and 
md_research_qual).  Model 2 includes the fixed-weight Medicaid drug vintage measure 
                                                 
17 By 2001, life expectancy of AIDS patients at time of diagnosis is estimated to have increased to about 26 
years. 
18 Estimates of models of the log of life expectancy at birth are quite consistent with these estimates.   18
vint_medicaid_rx_fixed (with fixed therapeutic-class weights) and both measures of 
physician quality (md_primcare_qual and md_research_qual).  Model 3 includes the 
fixed-weight Medicaid drug vintage measure and just the primary-care measure of 
physician quality.   
With only one exception, all of the indicators of the quality of medical care have 
positive and statistically significant effects on life expectancy in all three models.
19  In all 
three models, the advanced imaging coefficient is positive and highly significant (p-value 
< .003).  This signifies that life expectancy increased more rapidly (and that the age-
standardized mortality rate declined more rapidly) in states in which the fraction of 
Medicare imaging procedures that were advanced procedures increased more rapidly.  
Below we will discuss the magnitude of the estimated effect of the increased relative 
utilization of advanced imaging procedures on life expectancy.  But first we will review 
the signs and significance of the other variables included in models 1-3. 
The coefficients on both the basic Medicaid drug vintage measure (in model 1) 
and the fixed-weight Medicaid drug vintage measure (in models 2 and 3) are positive and 
highly significant.  The vintage of Medicare drug treatments also has a positive and 
highly significant effect.  Since expenditure on self-administered drugs is much larger 
than expenditure on provider-administered drugs, it is not surprising that the coefficients 
on Medicare drug vintage are much smaller than the coefficients on Medicaid drug 
vintage. 
Although the research-quality of medical schools attended by physicians is 
insignificant in model 1 and only marginally significant in model 2, the primary-care-
quality of medical schools attended by physicians is positive and significant in all three 
models.  Almost three fourths of the medical school primary care quality ranking is based 
on the following criteria: peer assessment score, assessment score by residency directors, 
student selectivity, faculty resources, mean MCAT score, mean undergraduate GPA, and 
acceptance rate.  States in which the primary-care-quality of medical schools attended by 
physicians declined more slowly had larger increases in life expectancy. 
                                                 
19 The exception is the research-quality of the medical schools attended by physicians.  Since U.S. News 
and World Report uses some of the same data to assess research quality as it does to assess primary-care 
quality, failure to detect an independent effect of research quality is not too surprising.   19
Now let’s consider the effects of three behavioral risk factors—obesity, AIDS, 
and smoking—on life expectancy.  As one would expect, the coefficient on the fraction 
of the population with a BMI greater than 25 and the coefficient on the AIDS incidence 
rate are negative and highly significant in models 1-3.  States with below-average 
increases in overweight/obesity prevalence and above-average declines in AIDS 
incidence had above-average increases in life expectancy during the period 1991-2004.  
Although the coefficient on smoking has the expected negative sign in all three models, it 
is insignificant in models 1 and 2 and only marginally significant (p-value=.09) in model 
3. 
Models 1-3 include three additional variables—health insurance coverage, 
educational attainment, and per capita income—that might be expected to affect life 
expectancy.  At the state level, long-term changes in life expectancy seem to be 
uncorrelated with changes in both health insurance coverage and educational 
attainment.
20  The life expectancy of a state’s residents appears to depend on education, 
but it is the quality of its physicians’ medical education, not the number of years of 
schooling of state residents that matters.  The coefficient on per capita income is negative 
and significant: states with high income growth had smaller longevity increases, ceteris 
paribus.  Some previous investigators have also found evidence of a non-monotonic or 
even inverse relationship between income and longevity.  Uchida et al (1992) found that 
“for [Japanese] females high income was the factor significantly decreasing life 
expectancy at 65 years of age in 1980.”  Hupfeld (2008) theoretically derived a non–
monotonic relationship between income and longevity, based on heterogeneous 
elasticities of labor supply and otherwise standard assumptions. He analyzed this 
relationship empirically for pensioners in the public pension system in Germany, and find 
that “the relationship between income and life expectancy is indeed non–monotonic for 
major sub–groups in the data.”  And Ruhm (2004) argued that “although health is 
conventionally believed to deteriorate during macroeconomic downturns, the empirical 
                                                 
20 The nature of the effect of health insurance coverage on life expectancy is not entirely clear on 
theoretical grounds.  Some analysts argue that people without health insurance receive necessary medical 
care, but that medical care is provided to them in an inefficient manner, e.g. in emergency rooms.  Also, 
low health insurance coverage could be partly due to decisions by young, healthy people not to enroll in 
health plans.  In that case, increases in coverage could be inversely correlated with increases in life 
expectancy.   20
evidence supporting this view is quite weak and comes from studies containing 
methodological shortcomings that are difficult to remedy. Recent research that better 
controls for many sources of omitted variables bias instead suggests that mortality 
decreases and physical health improves when the economy temporarily weakens. This 
partially reflects reductions in external sources of death, such as traffic fatalities and other 
accidents, but changes in lifestyles and health behaviors are also likely to play a role.” 
Now we will use the estimates of the parameters of models 1-3 to estimate the 
1991-2004 change in life expectancy that was attributable to each of the factors included 
in the models.  The change attributable to a factor X is calculated as follows: β (X2004 – 
X1991), where β is the coefficient on that factor, and X2004 and X1991 are the population-
weighted mean values of X in 2004 and 1991, respectively. These calculations are shown 
in Table 8.  Between 1991 and 2004, life expectancy at birth increased 2.37 years.
21  The 
estimates imply that the increased use of advanced imaging technology increased life 
expectancy by 0.62-0.71 years during this period.  The coefficient on the basic Medicaid 
drug vintage measure (vint_medicaid_rx) in model 1 implies that use of newer outpatient 
prescription drugs increased life expectancy by 1.26 years.  The coefficient on the fixed-
weight Medicaid drug vintage measure (vint_medicaid_rx_fixed) in models 2 and 3 
implies that the increase in life expectancy attributable to use of newer outpatient 
prescription drugs was about 20% smaller: 0.96-1.08 years.  The vint_medicare_rx 
coefficients imply that use of newer provider-administered drugs increased life 
expectancy by 0.48-0.54 years.  Overall, therefore, use of newer self- and provider-
administered drugs increased life expectancy by about 1.5 years. 
Although the average values of the first two indicators of the quality of medical 
care increased during the period 1991-2004, the average value of the quality of medical 
schools attended by practicing physicians declined.  Model 2 implies that the decline in 
both primary-care and research quality reduced life expectancy by 0.47 years; Model 3, 
which includes only the primary-care quality measure (the research quality measure is 
only marginally significant in model 2) implies that the decline in primary-care quality 
reduced life expectancy by 0.28 years. 
                                                 
21 Since the models include year fixed effects, the sum of the changes in life expectancy attributable to each 
of the factors need not be equal to the actual change in life expectancy.   21
Another factor that apparently reduced longevity growth during the period 1991-
2004 was the rise from 44% to 59% in the fraction of the population that was overweight 
or obese.  The estimates imply that this trend reduced the increase in life expectancy by 
.58-.68 years.  The increase in this risk factor was partly offset by a decline in another 
risk factor—the incidence of AIDS, which is estimated to have increased life expectancy 
by .18-.20 years.  The estimates also suggest that the small decline in smoking prevalence 
may have increased life expectancy by about 0.10 years.   
During the period 1991-2004, real per capita income (in 2006 dollars) increased 
from $21,102 to $25,465.
22   The estimates imply that this 19% increase in income 
reduced life expectancy by .34-.43 years.  The sum of the contributions of all of the 
factors to the increase in life expectancy is in the 0.85-1.32 year range.  Consequently, 
between 1.05 and 1.52 years of the 2.37-year increase in life expectancy is unexplained 
(i.e., captured by the year fixed effects). 
 
B.  Per capita medical expenditure 
 
Estimates of models of (the log of) per capita personal health care expenditure are 
shown in the bottom half of Table 7.  These models include the same regressors as the 
life expectancy models in the top of the table.  None of the coefficients on advanced 
imaging, drug vintage, or physician quality are statistically significant.  This indicates 
that, although states with larger increases in the quality of diagnostic procedures, drugs, 
and physicians had larger increases in life expectancy, they did not have larger increases 
in per capita medical expenditure.  This may be the case because, while newer diagnostic 
procedures and drugs are more expensive than their older counterparts, they may reduce 
the need for costly additional medical treatment.  The absence of a correlation across 
states between medical innovation and expenditure growth is inconsistent with the view 
                                                 
22 Source: U.S. Census Bureau, Historical Income Tables – People, Table P-1. CPS Population and Per 
Capita, Money Income, All Races: 1967 to 2006, 
http://www.census.gov/hhes/www/income/histinc/p01ar.html   22
expressed by the Kaiser Family Foundation (2007), citing Rettig (1994), that “advances 
in medical technology have contributed to rising overall U.S. health care spending.” 
The prevalence of obesity and smoking do not appear to affect per capita medical 
expenditure, but the incidence of AIDS has a significant positive effect.  This is to be 
expected, since Duggan and Evans (2008) estimated that in California during the period 
1994-2003, average annual Medicaid medical expenditure (the sum of pharmaceutical, 
outpatient and inpatient expenditure) per AIDS patient was about $18,800. 
Increased health insurance coverage is associated with lower growth in per capita 
medical expenditure.  One possible explanation is that lack of employer-based health 
insurance (which may result from employment in high-turnover industries) causes under-
investment in the health of workers and higher medical expenditure in retirement.  Fang 
and Gavazza (2007) found that employers in industries with high turnover rates are much 
less likely to offer health insurance to their workers, and that individuals who were 
employed in high turnover industries have higher medical expenditure when retired. 
Growth in per capita medical expenditure is also positively correlated with growth 
in educational attainment and (more weakly) with income growth.  Many previous 
studies have shown that medical care is a normal good (income elasticity greater than 
zero); some studies (Gerdtham and Jonsson (2000)) suggest that it is a luxury good 
(income elasticity greater than one). 
 
V.  Some additional evidence (based on Australian data) about the impact of 
advanced imaging technology on mortality 
 
The availability of data from Australia’s universal health care system, Medicare 
Australia, allows us to provide some additional evidence about the impact of advanced 
imaging technology on mortality.  Medicare Australia was introduced in 1984 to provide 
eligible Australian residents with affordable, accessible and high-quality health care.  
Medicare was established based on the understanding that all Australians should 
contribute to the cost of health care according to their ability to pay. It is financed 
through progressive income tax and an income-related Medicare levy.  Medicare provides 
access to free treatment as a public (Medicare) patient in a public hospital, and free or   23
subsidized treatment by medical practitioners including general practitioners, specialists, 
participating optometrists or dentists (for specified services only). 
On its website, Medicare Australia publishes data on the number of services 
provided, by category (e.g. Category 5: Diagnostic Imaging Services), group (e.g. Group 
I2: Computerised Tomography), state, gender, age group (10 age groups: 0-4 years, 5-14 
years, 15-24 years, etc.), and year (1995-2008).
23  Hence, we can compute the number of 
advanced imaging (computerised tomography and magnetic resonance imaging) 
procedures and the number of standard imaging procedures (all other diagnostic imaging 
procedures) performed, by demographic group (gender/age group), region,
24 and year.
25  
The GRIM (General Record of Incidence of Mortality) books
26 published by the 
Australian Institute of Health and Welfare contain data on population and number of 
deaths, by demographic group (gender/age group), region, and year.  Hence, we can 
computer the following variables, for 20 gender-age groups, 5 regions, and 10 years: 
 
N_ADV_IMAGEgrt  = the number of advanced imaging procedures performed on 
members of gender-age group g in region r in year t 
N_STD_IMAGEgrt  = the number of standard imaging procedures performed on 
members of gender-age group g in region r in year t 
POPgrt  = the population of gender-age group g in state s in year t 
N_DEATHSgrt  = the number of deaths in gender-age group g in region r in year t 
 
These data enable us to estimate difference-in-difference models of the effect of 
advanced imaging innovation on age-specific mortality rates.  We will estimate several 
different model specifications.  The first two will be estimated at the national level, by 
aggregating the regional data.  The first specification is: 
 




                                                 
23 https://www.medicareaustralia.gov.au/statistics/mbs_group.shtml  
24 Australia consists of eight states, and the MRI procedure data are aggregated to five regions. 
25 Medicare Australia also publishes data on prescription drug utilization by state and year, but not by 
demographic group. 
26 http://www.aihw.gov.au/mortality/data/grim_books.cfm   24
MORT_RATEg.t = ∑r N_DEATHSgrt / ∑r POPgrt = the mortality rate of group g in 
year t 
ADV_IMAGE%g.t = ∑r N_ADV_IMAGEgrt / (∑r N_ADV_IMAGEgrt +  
∑r N_STD_IMAGEgrt) = the fraction of imaging procedures 
performed on members of demographic group g in year t that were 
advanced procedures 
 
In this specification, diagnostic imaging innovation is measured in the same way as it was 
measured in our models of U.S. life expectancy and per capita medical expenditure.   
This specification may be less appropriate when analyzing data on a panel of 
demographic groups than when analyzing data on a panel of regions.  The effect on the 
mortality rate of an increase in the fraction of procedures that are advanced procedures is 
likely to be greater, the larger the number of procedures per capita.  As shown in Figure 
11, there is enormous variation across age groups in the number of diagnostic imaging 
services performed per 100,000 population.
27  In light of this, a more appropriate 
specification is likely to be: 
log (MORT_RATEg.t / (1 - MORT_RATEg.t)) = βA (∑r N_ADV_IMAGEgrt / ∑r POPgrt)  
  + βS (∑r N_STD_IMAGEgrt / ∑r POPgrt) + αg + δt + εg.t             (3) 
 
We will also estimate analogous models using data by demographic group, region, and 
year, including fixed region-year interaction effects as well as fixed demographic group 
effects: 
 
log (MORT_RATEgrt / (1 - MORT_RATEgrt)) = β ADV_IMAGE%grt + αg + δrt + εgrt   (4) 
 
log (MORT_RATEgrt / (1 - MORT_RATEgrt)) = βA (N_ADV_IMAGEgrt / POPgrt)  
  + βS (N_STD_IMAGEgrt / POPgrt) + αg + δrt + εgrt                     (5) 
 
Estimates of the parameters of eqs. _-_ are shown in Table 9.  Line 1 shows the 
estimate of the ADV_IMAGE% coefficient based on nation-level data.  It has the 
expected negative sign but is not statistically significant.  Lines 2-3 show the estimates of 
the coefficients of eq. ( ).  The coefficient on the number of advanced imaging procedures 
                                                 
27 There is much less variation in procedure intensity across regions.   25
per capita is negative and significant, while the coefficient on the number of standard 
imaging procedures per capita is insignificant.  This indicates that demographic groups 
that had above-average increases in the number of advanced imaging procedures per 
capita had above-average declines in mortality rates, but that changes in mortality rates 
were uncorrelated across demographic groups with changes in the number of standard 
imaging procedures per capita.   
Figure 12 illustrates the relationship across demographic groups between the 
1995-2004 increase in the number of advanced imaging procedures per capita and the 
1995-2004 reduction in the log of the mortality rate.  Groups below age 35 are excluded; 
these jointly accounted for less than 5% of deaths in 2004.  For both genders, the age 
profiles of the increase in the number of advanced imaging procedures per capita and the 
reduction in the log of the mortality rate have inverted-U shapes, and are at a maximum 
in the 65-74 year age group.   
The estimate of the coefficient of (N_ADV_IMAGE / POP) in line 2 implies that 
the increase in the number of advanced imaging procedures per capita accounted for 
about 46% of the decline in the age-adjusted Australian mortality rate during the period 
1995-2005.  Due to data limitations, we are unable to control for other potential 
determinants of mortality, such as drug vintage, physician quality, and behavioral risk 
factors.  Since these data are available for the U.S., we can calculate the effect of 
controlling for these other variables on the estimate of the effect of diagnostic imaging 
innovation on longevity.  As shown in Table 7, the coefficient on adv_image% in Model 
1, controlling for the other included variables, is 6.463.  This implies that increased use of 
diagnostic imaging innovation increased U.S. life expectancy by 0.62 years during 1991-
2004: 26% of the total increase.  If we estimate Model 1 excluding variables other than 
adv_image%, the coefficient on this variable is 11.102 (Z = 2.88; p-value = 0.0040).  
This would imply that increased use of diagnostic imaging innovation increased U.S. life 
expectancy by 1.06 years during 1991-2004: 45% of the total increase.  The latter is 
almost identical to our estimate based on Australian data.  Therefore it seems reasonable 
to conclude that controlling for the other variables included in the model of U.S. life 
expectancy would reduce the estimate of the coefficient of (N_ADV_IMAGE / POP) by 
about 40%, which would imply that increased use of diagnostic imaging innovation   26
accounted for 26% of the total increase in Australian life expectancy during the period 
1995-2004.
28 
The estimates based on region-level data, shown in lines 4-6 of Table 9, are 
similar to the estimates based on nation-level data.  The region-level estimate of the 
ADV_IMAGE% coefficient (line 4) is also insignificant.  The region-level coefficient on 
the number of advanced imaging procedures per capita (line 5) is negative and 
significant, and its magnitude is close to the nation-level estimate (line 2).  The region-
level coefficient on the number of standard imaging procedures per capita is positive and 
significant.  This indicates that demographic groups that had above-average increases in 
the number of standard imaging procedures per capita had below-average declines in 
mortality rates.  Groups that had above-average increases in the number of standard 
imaging procedures per capita may have experienced unobserved negative health shocks. 
 
VI.  Summary 
 
The rate of increase of longevity has varied considerably across U.S. states since 
1991.  This paper has examined the effect of the quality of medical care, behavioral risk 
factors, and other variables on life expectancy and medical expenditure using longitudinal 
state-level data.   
We examined the effects of three different measures of the quality of medical 
care.  The first is the average quality of diagnostic imaging procedures, defined as the 
fraction of procedures that are advanced procedures.  The second is the average quality of 
practicing physicians, defined as the fraction of physicians that were trained at top-ranked 
medical schools.  The third is the mean vintage (FDA approval year) of outpatient and 
inpatient prescription drugs.   
We also examined the effects on longevity of three important behavioral risk 
factors—obesity, smoking, and AIDS incidence—and other variables—education, 
income, and health insurance coverage—that might be expected to influence longevity 
growth.  Our econometric approach controlled for the effects of unobserved factors that 
                                                 
28 Australian life expectancy has been increasing faster than U.S. life expectancy.  Between 1995 and 2003, 
Australian life expectancy increased 2.4 years, from 77.9 to 80.3 years, while U.S. life expectancy 
increased 1.8 years, from 75.7 to 77.5 years.  Source: OECD Health Database.   27
vary across states but are relatively stable over time (e.g. climate and environmental 
quality), and unobserved factors that change over time but are invariant across states (e.g. 
changes in Federal government policies). 
Our indicators of the quality of diagnostic imaging procedures, drugs, and 
physicians almost always had positive and statistically significant effects on life 
expectancy.  Life expectancy increased more rapidly in states where (1) the fraction of 
Medicare diagnostic imaging procedures that were advanced procedures increased more 
rapidly; (2) the vintage of self- and provider-administered drugs increased more rapidly; 
and (3) the quality of medical schools previously attended by physicians increased more 
rapidly. 
Between 1991 and 2004, life expectancy at birth increased 2.37 years.  The 
estimates imply that, during this period, the increased use of advanced imaging 
technology increased life expectancy by 0.62-0.71 years, use of newer outpatient 
prescription drugs increased life expectancy by 0.96-1.26 years, and use of newer 
provider-administered drugs increased life expectancy by 0.48-0.54 years.  The decline in 
the average quality of medical schools previously attended by physicians reduced life 
expectancy by 0.28-0.47 years. 
The rise from 44% to 59% in the fraction of the population that was overweight or 
obese reduced the increase in life expectancy by .58-.68 years.  The decline in the 
incidence of AIDS is estimated to have increased life expectancy by .18-.20 years.  The 
small decline in smoking prevalence may have increased life expectancy by about 0.10 
years.   
Growth in life expectancy was uncorrelated across states with health insurance 
coverage and education, and inversely correlated with per capita income growth.  The 
19% increase in real per capita income is estimated to have reduced life expectancy by 
.34-.43 years.  The sum of the contributions of all of the factors to the increase in life 
expectancy is in the 0.85-1.32 year range.  Consequently, between 1.05 and 1.52 years of 
the 2.37-year increase in life expectancy is unexplained. 
Although states with larger increases in the quality of diagnostic procedures, 
drugs, and physicians had larger increases in life expectancy, they did not have larger 
increases in per capita medical expenditure.  This may be the case because, while newer   28
diagnostic procedures and drugs are more expensive than their older counterparts, they 
may reduce the need for costly additional medical treatment.  The absence of a 
correlation across states between medical innovation and expenditure growth is 
inconsistent with the view that advances in medical technology have contributed to rising 
overall U.S. health care spending.  Increased health insurance coverage is associated with 
lower growth in per capita medical expenditure.   
The availability of data from Australia’s universal health care system, Medicare 
Australia, allowed us to provide some additional evidence about the impact of advanced 
imaging technology on mortality.  We estimated difference-in-difference models of the 
effect of advanced imaging innovation on age-specific mortality rates.  Demographic 
groups that had above-average increases in the number of advanced imaging procedures 
per capita had above-average declines in mortality rates, but changes in mortality rates 
were uncorrelated across demographic groups with changes in the number of standard 
imaging procedures per capita.  Estimates of the effect of diagnostic imaging innovation 
on longevity based on Australian data are quite consistent with estimates based on U.S. 
data. 
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Harvard University (MA) 1 13
Johns Hopkins University (MD) 2 28
University of Pennsylvania 3 16
Washington University in St. Louis 4 38
University of California–San Francisco 5 8
University of Washington 6 1
Stanford University (CA) 7 .
Duke University (NC) 8 34
Yale University (CT) 8 .
Baylor College of Medicine (TX) 10 11
University of Michigan–Ann Arbor 10 45
Columbia U. College of Physicians and Surgeons (NY) 10 57
University of California–Los Angeles (Geffen) 13 18
University of California–San Diego 14 38
University of Pittsburgh 15 18
University of Chicago (Pritzker) 15 53
Cornell University (Weill) (NY) 15 .
Vanderbilt University (TN) 18 30
U. of Texas Southwestern Medical Center–Dallas 19 18
University of North Carolina–Chapel Hill 20 2
Source: U.S. News and World Report
Table 1
Research ranking and primary care ranking of top 20 medical schools, 
ranked by research rankingYear Number of 
physicians % of physicians who were 
graduates from top 60 
medical schools ranked in 
terms of research
% of physicians who were 
graduates from top 60 
medical schools ranked in 
terms of primary care
1991 582,910 45.2% 40.0%
1992 596,337 44.7% 39.7%
1993 590,583 44.7% 40.0%
1994 640,044 44.1% 39.5%
1995 647,064 43.7% 39.3%
1996 664,096 43.6% 39.2%
1997 681,343 43.5% 39.2%
1998 713,856 42.9% 38.8%
1999 743,261 42.4% 38.4%
2000 756,868 42.5% 38.6%
2001 771,381 42.1% 38.3%
2002 791,496 41.6% 38.0%
2003 810,648 41.4% 37.8%
2004 818,732 41.0% 37.5%
Table 2
Percent of physicians who were graduates of top-ranked medical schools, 1991-2004Major therapeutic class
1991 2004 1991 2004
central nervous system medications 19% 29% 1967.6 1984.1
cardiovascular medications 21% 21% 1975.6 1982.1
antimicrobials 16% 9% 1970.4 1982.2
hormones/synthetics/modifiers 7% 8% 1971.6 1978.2
gastrointestinal medications 5% 6% 1978.4 1993.8
respiratory tract medications 7% 6% 1976.6 1986.6
musculoskeletal medications 7% 4% 1975.6 1987.5
antihistamines 3% 3% 1953.7 1976.4
dermatological agents 5% 3% 1968.7 1972.8
blood products/modifiers/volume expanders 1% 2% 1956.3 1986.7
ophthalmic agents 2% 2% 1972.3 1988.6
nasal and throat agents,topical 1% 2% 1974.1 1984.7
autonomic medications 2% 1% 1961.0 1974.3
therapeutic nutrients/minerals/electrolytes 2% 1% 1971.2 1972.4
genitourinary medications 1% 1% 1977.4 1980.9
vitamins 0% 1% 1952.1 1962.3
antineoplastics 0% 0% 1969.8 1976.3
immunological agents 0% 0% 1976.0 1992.0
dental and oral agents,topical 0% 0% 1962.6 1972.3
antiparasitics 1% 0% 1976.2 1972.7
antidotes,deterrents and poison control 0% 0% 1967.5 1975.6
pharmaceutical aids/reagents 0% 0% 1972.1 1971.5
irrigation/dialysis solutions 0% 0% 1968.9 1969.2
otic agents 0% 0% 1958.8 1988.5
rectal,local 0% 0% 1959.1 1976.2
miscellaneous agents 0% 0% 1950.0 1993.9
diagnostic agents 0% 0% 1957.5 1957.1
prosthetics/supplies/devices 0% 0% 1985.0 1985.0
Note: therapeutic classes are ranked by share of Rx's in 2004.
share of rx's Mean vintage
Table 3
Distribution and vintage of Medicaid prescriptions in 1991 and 2004, by major therapeutic 



































dexamethasone sodium phosphate 19,764,089



















Top 25 active ingredients contained in 2004 Medicare drug treatments, 


























































































































































































































































































1991 75.5 9.3% 1971.4 1971.2 1973.6 45.5% 41.4% $19,743 86.1% 4.53 23.8% 44.5% 16.9 $2,634 241.8
1992 75.8 9.5% 1971.7 1971.6 1975.2 44.9% 41.1% $20,715 85.8% 4.55 23.1% 46.4% 18.9 $2,819 245.0
1993 75.6 9.6% 1972.1 1972.2 1976.6 44.9% 41.4% $21,216 87.1% 4.58 22.6% 47.3% 23.1 $2,942 241.3
1994 75.8 9.6% 1972.6 1972.9 1980.1 44.4% 40.9% $22,074 86.9% 4.52 22.4% 48.4% 29.7 $3,080 256.4
1995 75.9 9.8% 1973.2 1973.6 1981.5 44.1% 40.7% $23,012 87.7% 4.57 22.2% 49.4% 29.7 $3,225 254.0
1996 76.3 10.4% 1974.1 1974.6 1982.8 44.0% 40.7% $24,111 86.7% 4.64 23.2% 50.3% 27.1 $3,360 256.9
1997 76.6 11.3% 1975.1 1975.9 1983.4 43.9% 40.6% $25,273 86.9% 4.65 22.7% 51.3% 25.4 $3,502 259.9
1998 76.8 11.9% 1976.1 1977.1 1985.0 43.4% 40.2% $26,815 86.8% 4.66 22.8% 52.9% 21.9 $3,645 264.7
1999 76.8 12.8% 1977.1 1978.4 1986.1 42.8% 39.9% $27,794 86.9% 4.66 22.6% 54.2% 17.4 $3,815 273.3
2000 77.0 13.8% 1978.2 1979.8 1987.2 42.8% 39.9% $29,663 87.3% 4.71 22.5% 55.2% 14.7 $4,027 276.3
2001 77.1 15.1% 1978.9 1980.7 1988.3 42.3% 39.5% $30,407 87.5% 4.73 22.7% 56.7% 13.7 $4,332 279.0
2002 77.2 16.0% 1979.7 1981.6 1989.3 41.9% 39.2% $30,661 87.0% 4.75 21.6% 57.2% 13.1 $4,643 281.7
2003 77.4 16.7% 1980.3 1982.4 1990.7 41.5% 38.9% $31,340 86.9% 4.76 21.2% 58.4% 12.1 $4,954 284.4
2004 77.9 18.8% 1980.7 1982.6 1992.2 41.0% 38.5% $32,888 86.7% 4.76 20.0% 59.4% 8.4 $5,293 287.1
Table 6
Population-weighted means of key variables, by yearIndependent variable Estimate Z ProbZ Estimate Z ProbZ Estimate Z ProbZ
adv_image% 6.463 2.951 0.003 6.825 3.176 0.001 7.446 3.277 0.001
vint_medicaid_rx 0.135 3.965 0.000
vint_medicaid_rx_fixweight 0.085 2.806 0.005 0.095 2.992 0.003
vint_medicare_rx 0.029 2.906 0.004 0.026 2.658 0.008 0.026 2.415 0.016
md_primcare_qual 6.828 2.458 0.014 7.013 2.562 0.010 9.709 3.085 0.002
md_research_qual 5.086 1.381 0.167 6.219 1.839 0.066
bmi_gt25 -3.869 -2.521 0.012 -4.465 -2.823 0.005 -4.532 -2.885 0.004
aids_pop -0.021 -5.136 0.000 -0.021 -4.504 0.000 -0.023 -5.924 0.000
now_smoke -1.618 -1.074 0.283 -2.181 -1.467 0.142 -2.570 -1.716 0.086
health_cov 0.645 0.483 0.629 1.356 1.013 0.311 1.502 1.135 0.257
edu -0.004 -0.015 0.988 0.011 0.046 0.963 -0.039 -0.156 0.876
income -1.834 -1.879 0.060 -2.070 -2.223 0.026 -2.272 -2.221 0.026
Independent variable Estimate Z ProbZ Estimate Z ProbZ Estimate Z ProbZ
adv_image% 0.377 1.413 0.158 0.379 1.411 0.158 0.336 1.345 0.179
vint_medicaid_rx -0.003 -0.458 0.647
vint_medicaid_rx_fixweight -0.004 -0.972 0.331 -0.005 -1.197 0.231
vint_medicare_rx -0.001 -1.136 0.256 -0.001 -1.071 0.284 -0.001 -1.070 0.285
md_primcare_qual -0.420 -0.939 0.348 -0.436 -0.994 0.320
md_research_qual 0.209 0.424 0.672 0.232 0.468 0.640 0.043 0.097 0.923
bmi_gt25 0.078 0.658 0.510 0.095 0.774 0.439 0.100 0.823 0.410
aids_pop 0.002 2.048 0.041 0.002 2.005 0.045 0.002 2.080 0.038
now_smoke 0.261 1.200 0.230 0.272 1.187 0.235 0.300 1.320 0.187
health_cov -0.403 -2.042 0.041 -0.397 -1.864 0.062 -0.407 -1.984 0.047
edu 0.101 2.344 0.019 0.103 2.408 0.016 0.106 2.484 0.013
income 0.256 1.692 0.091 0.252 1.650 0.099 0.267 1.761 0.078
Table 7
Estimates of models of life expectancy and per capita personal health care expenditure
Dependent variable: log of per capita personal health care expenditure
Dependent variable: life expectancy at birth
Model 1 Model 2 Model 3
The estimates are weighted least-squares estimates, weighting by state population.  All equations include fixed state effects and fixed year effects.  Standard errors 
are clustered within states.
Model 4 Model 5 Model 6change, 1991-2004 Model 1 Model 2 Model 3
life expectancy at birth 2.37
adv_image% 0.10 0.62 0.65 0.71
vint_medicaid_rx 9.34 1.26
vint_medicaid_rx_fixweight 11.37 0.96 1.08
vint_medicare_rx 18.56 0.54 0.49 0.48
md_primcare_qual -0.03 -0.19 -0.20 -0.28
md_research_qual -0.04 -0.22 -0.27
bmi_gt25 0.15 -0.58 -0.67 -0.68
aids_pop -8.49 0.18 0.18 0.20
now_smoke -0.04 0.06 0.08 0.10
health_cov 0.01 0.00 0.01 0.01
edu 0.23 0.00 0.00 -0.01
income 0.19 -0.34 -0.39 -0.43
total 1.32 0.85 1.18
unexplained 1.05 1.52 1.19
Estimated effect of change on 
1991-2004 change in life 
expectancy
Table 8
Calculation of the 1991-2004 change in life expectancy that was attributable to 
various factorsLine Equation Parameter Estimate Z Pr > |Z|
1 2 ADV_IMAGE% -1.411 -1.180 0.237
2 3 N_ADV_IMAGE / POP -1.592 -2.000 0.046
3 3 N_STD_IMAGE / POP 0.130 0.680 0.494
4 4 ADV_IMAGE% -0.470 -1.170 0.241
5 5 N_ADV_IMAGE / POP -1.493 -3.190 0.001
6 5 N_STD_IMAGE / POP 0.225 2.770 0.006
National level (N = 240)
Regional level (N = 1100)
Equations _ and _ include fixed demographic-group effects and fixed year effects.  Equations 
_ and _ include fixed demographic-group effects and fixed region-year interaction effects.  
Standard errors are clustered within demographic groups.
Table 9
Estimates of the effect of medical imaging innovation on Australian age-specific 
mortality rates  34
 
Figure 1 
Increase in life expectancy at birth 1991-2004, by state 
 
 Figure 3
Number of advanced imaging procedures as % of 












1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004  35
Figure 4 
 
Number of advanced imaging procedures in 2004 as 
% of number of standard + advanced procedures in 2004 
 
advanced 16%  -  17% 17%  -  18% 18%  -  19%
19%  -  19% 19%  -  20% 20%  -  24%
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Figure 5 
 
Fraction of practicing physicians who graduated from the  
top 60 medical schools ranked in terms of research, by state, 2004 
research12 2%  -  23% 23%  -  30% 33%  - 3 8 %
38%  -  48% 49%  -  58% 58%  - 6 7 %
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Figure 6 
Fraction of practicing physicians who graduated from the  
top 60 medical schools ranked in terms of primary care, by state, 2004 
pr i m ar y12 1%  -  24% 26%  -  32% 33%  -  39%
41%  -  49% 50%  -  58% 59%  -  64%
 Figure 7
Annual incidence rates (cases per 100,000) of 
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Figure 10 
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The relationship across demographic groups between the 1995-2004 increase in the 
number of advanced imaging procedures per capita and the 1995-2004 reduction in the 
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 Appendix A 
 
Medicine Methodology - US News and World Report 
 
The 125 medical schools fully accredited by the Liaison Committee on Medical 
Education plus the 20 schools of osteopathic medicine fully accredited by the American 
Osteopathic Association were surveyed in the fall 2007 and early 2008. In order to 
determine the ranking of research medical schools; 126 schools responded to the survey. 
Of these schools, 126 provided the data needed to calculate the research rankings based 
on the indicators used in the research model.  The same medical and osteopathic schools 
were surveyed for the primary-care ranking; 126 schools provided the data needed to 
calculate the primary-care ranking. The medical school research model is based on a 
weighted average of eight indicators, and the primary-care model is based on seven 
indicators. Both rankings are based on a weighted average of indicators, four of 
the data indicators are used in both the research and primary-care ranking model. The 
research model factors in research activity; the primary-care model adds a measure of the 
proportion of graduates entering primary-care specialties. 
 
Quality Assessment (weighted by .40) 
Peer Assessment Score (.20 for the research medical school model, .25 for the 
primary-care medical school model) In the fall of 2007, medical and osteopathic school 
deans, deans of academic affairs, and heads of internal medicine or the directors of 
admissions were asked to rate programs on a scale from "marginal" (1) to "outstanding" 
(5). Survey populations were asked to rate program quality for both research and 
primary-care programs 
separately on a single survey instrument. Those individuals who did not know enough 
about a school to evaluate it fairly were asked to mark "don't know." A school's score is 
the average of all the respondents who rated it. Responses of "don't know" counted 
neither for nor against a school. About 48 percent of those surveyed responded. 
Assessment Score by Residency Directors (.20 for the research medical school 
model, .15 for the primary-care medical school model) In the fall of 2007, residency 
program directors were asked to rate programs on two separate survey instruments. One 
survey dealt with research and was sent to a sample of residency program directors in 
fields outside primary care, including surgery, psychiatry, and radiology. The other 
survey involved primary care and was sent to residency directors in the fields of family 
practice, pediatrics, and internal medicine. Survey recipients were asked to rate programs 
on a scale from "marginal" (1) to "outstanding" (5). Those individuals who did not know 
enough about a program to evaluate it fairly were asked to mark "don't know." A school's 
score is the average of all the respondents who rated it. Responses of "don't know" 
counted neither for nor against a school. About 25 percent of those surveyed for research 
medical schools responded; eighteen percent responded for primary-care.  The source for 
the names for both of the residency directors surveys was the Graduate Medical 
Education Directory 2006-2007 edition, published by the American Medical Association. 
The peer scores from the America's Best Graduate Schools 2008 edition's residency 
directors' survey in non-primary care fields were used again for all schools in the research   40
medical school model because of a printing error on the survey instrument mailed out in 
fall 2007. Assessment data collected by Synovate. 
Research Activity (weighted by .30 in the research medical school model only) 
Total Research Activity (.20) Measured by the total dollar amount of National Institutes 
of Health research grants awarded to the medical school and its affiliated hospitals, 
averaged for 2006 and 2007. An asterisk indicates schools that reported only research 
grants to their medical school in 2007. 
Average Research Activity Per Faculty Member (.10) Measured by the dollar amount 
of National Institutes of Health research grants awarded to the medical school and its 
affiliated hospitals per full-time faculty member, averaged over 2006 and 2007. Both full-
time basic sciences and clinical faculty were used in the faculty count. An asterisk 
indicates schools that reported research grants only to their medical school in 2007. 
Primary-Care Rate (.30 in the primary-care medical school model only) The 
percentage of M.D. or D.O. school graduates entering primary-care residencies in the 
fields of family practice, pediatrics, and internal medicine was averaged over 2005, 2006, 
and 2007. 
Student Selectivity (.20 in the research medical school model, .15 in the primary-
care medical school model) 
Mean MCAT Score (.13 in the research medical school model, .0975 in the primary-
care medical school model) The mean composite Medical College Admission Test score 
of the 2007 entering class. 
Mean Undergraduate GPA (.06 in the research medical school model, .045 in the 
primary-care medical school model) The mean undergraduate grade-point average of 
the 2007 entering class. 
Acceptance Rate (.01 in the research medical school model, .0075 in the primary-
care medical school model) The proportion of applicants to the 2007 entering class who 
were offered admission. 
Faculty Resources (.10 in the research medical school model, .15 in the primary-care 
medical school model) Faculty Resources were measured as the ratio of full-time science 
and full-time clinical faculty to full-time M.D. or D.O. students in 2007. 
Overall Rank: Indicators were standardized about their means, and standardized scores 
were weighted, totaled, and rescaled so that the top school received 100; other schools 
received their percentage of the top score. 
Specialty Rankings: The rankings are based solely on ratings by medical school deans 
and senior faculty from the list of schools surveyed. They each identified up to 10 schools 
offering the best programs in each specialty area. Those receiving the most nominations 
appear here.   41
Appendix B 
 
Correlation across states between changes in the vintage of Medicaid and non-
Medicaid prescriptions 
 
  This appendix describes a test of the hypothesis that the extent of utilization of 
new drugs in the Medicaid program is strongly correlated with the extent of utilization of 
new drugs in general.  We had access to data from a private company, NDCHealth, on 
the number of prescriptions, by NDC code, state (and five U.S. territories), month 
(January 2001-December 2003), and payer (Medicaid, other third party, and cash), for six 
important therapeutic classes of drugs: antidepressants, antihypertensives, cholesterol-
lowering drugs, diabetic drugs, osteoporosis/menopause drugs, and pain management 
medications.  Here are some summary statistics: 
 
 N  mean  std  dev.  min  max 
  FDA approval year 
Medicaid 252,469,702  1986.44 1.51474 1961.22 2002
Other 2,244,589,497  1986.59 1.19334 1980.47 1999
Total 2,497,059,199  1986.58 1.18352 1980.85 1999
         
  share of Rx's for drugs approved after 1980 
Medicaid 252,469,702  0.81739 0.04221 0 1
Other 2,244,589,497  0.80292 0.02936 0.5 1
Total 2,497,059,199  0.80438 0.0297 0.5 1
 
These data were used to estimate the following equation:
29 
 
Yit = π VINT_MEDICAIDit + αi + δt + εit   (2) 
where  
 
VINT_MEDICAIDit  = the mean vintage (FDA approval year) of Medicaid rx’s in state i 
in month t 
Yit  = the mean vintage of all rx’s or of non-Medicaid (third-party and 
cash) rx’s in state i in month t 
αi  = a fixed effect for state i 
δt  = a fixed effect for year t 
εit  = a disturbance 
 
                                                 
29 This equation was estimated by weighted least-squares, weighting by the total number of rx’s, or the 
number of non-Medicaid rx’s, in state i in month t.   42
Two alternative measures of vintage were used: the mean FDA approval year, and the 
share of prescriptions containing active ingredients approved after 1980.  Estimates of eq. 
(1) are shown in Table 1.  In all four equations, the estimate of π is positive and highly 
statistically significant (p-value <.0001).  This indicates that the extent of utilization of 
new drugs in the Medicaid program is strongly correlated with the extent of utilization of 
new drugs in general.  The vintage of non-Medicaid (and all) rx’s tended to increase more 
in states with larger increases in the vintage of Medicaid rx’s.   
 Model 1a 1b 2a 2b
Dependent 
Variable
mean FDA approval 
year of all rx's




mean FDA approval 
year of third-party & 
cash rx's
share of third-party & 




mean FDA approval 
year of Medicaid 
rx's




mean FDA approval 
year of Medicaid rx's
share of Medicaid 
rx's containing active 
ingredients approved 
after 1980
Weight total number of rx's total number of rx's
number of third-party 
+ cash rx's
number of third-party 
+ cash rx's
π 0.291 0.316 0.237 0.253
std. err. 0.012 0.013 0.013 0.014
t-stat 25.19 23.98 18.98 17.75
p-value <.0001 <.0001 <.0001 <.0001
Appendix Table 1
The relationship between the vintage of Medicaid rx's and the vintage of other (or all) rx's